{"id":39380,"date":"2020-08-11T13:37:43","date_gmt":"2020-08-11T13:37:43","guid":{"rendered":"https:\/\/setterwalls.se\/case\/setterwalls-advises-saniona-in-connection-with-directed-issue-of-approximately-sek-567-million\/"},"modified":"2022-02-14T13:44:19","modified_gmt":"2022-02-14T13:44:19","slug":"setterwalls-advises-saniona-in-connection-with-directed-issue-of-approximately-sek-567-million","status":"publish","type":"assignments","link":"https:\/\/setterwalls.se\/en\/case\/setterwalls-advises-saniona-in-connection-with-directed-issue-of-approximately-sek-567-million\/","title":{"rendered":"Setterwalls advises Saniona in connection with directed issue of approximately SEK 567 million"},"content":{"rendered":"<p><strong>Setterwalls has advised Saniona AB in connection with a directed issue to a number of U.S. and international institutional investors and sector specialists.<\/strong><\/p>\n<p>Saniona AB, a rare disease biopharmaceutical company focused on research, development and commercialization of treatments for the central nervous system, has carried out a directed issue that provides the company with gross proceeds of USD 65 million (approximately SEK 567 million). The new issue was directed to a number of U.S. and international institutional investors and sector specialists.<\/p>\n<p>The issue proceeds will be used to continue Saniona\u2019s advancement of its late-stage clinical trials with the product candidate Tesomet in two rare eating disorders, hypothalamic obesity and Prader Willi Syndrome, as well as to build its U.S.-based organization in support of the company\u2019s clinical development programs.<\/p>\n","protected":false},"excerpt":{"rendered":"<p><strong>Setterwalls has advised Saniona AB in connection with a directed issue to a number of U.S. and international institutional investors and sector specialists.<\/strong><\/p>\n<p>Saniona AB, a rare disease biopharmaceutical company focused on research, development and commercialization of treatments for the central nervous system, has carried out a directed issue that provides the company with gross proceeds of USD 65 million (approximately SEK 567 million). The new issue was directed to a number of U.S. and international institutional investors and sector specialists.<\/p>\n<p>The issue proceeds will be used to continue Saniona\u2019s advancement of its late-stage clinical trials with the product candidate Tesomet in two rare eating disorders, hypothalamic obesity and Prader Willi Syndrome, as well as to build its U.S.-based organization in support of the company\u2019s clinical development programs.<\/p>\n","protected":false},"author":1,"featured_media":34174,"template":"","meta":{"_acf_changed":false,"_seopress_robots_primary_cat":"","_seopress_titles_title":"","_seopress_titles_desc":"","_seopress_robots_index":""},"class_list":["post-39380","assignments","type-assignments","status-publish","has-post-thumbnail","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/setterwalls.se\/en\/wp-json\/wp\/v2\/assignments\/39380","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/setterwalls.se\/en\/wp-json\/wp\/v2\/assignments"}],"about":[{"href":"https:\/\/setterwalls.se\/en\/wp-json\/wp\/v2\/types\/assignments"}],"author":[{"embeddable":true,"href":"https:\/\/setterwalls.se\/en\/wp-json\/wp\/v2\/users\/1"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/setterwalls.se\/en\/wp-json\/wp\/v2\/media\/34174"}],"wp:attachment":[{"href":"https:\/\/setterwalls.se\/en\/wp-json\/wp\/v2\/media?parent=39380"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}